Meeting
2016 ASCO Annual Meeting
Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).
Authors
Shun Lu
Shanghai Chest Hospital, Jiao Tong University, Shanghai, China
Shun Lu , Tony Mok , You Lu , Jianying Zhou , Yuankai Shi , Virote Sriuranpong , James C. M. Ho , Choo Khoon Ong , Chun-Ming Tsai , Chin-Hee Chung , Keith D. Wilner , Yiyun Tang , Elizabeth Masters , Paulina Selaru , Yi-Long Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01639001
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9058)
DOI
10.1200/JCO.2016.34.15_suppl.9058
Abstract #
9058
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
First Author: Tony Mok
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2013 ASCO Annual Meeting
65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
First Author: Wolfgang Schuette
Poster
2023 ASCO Annual Meeting
Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
First Author: Rajwanth Veluswamy